RARE vs RGS · rev $350.0M vs P/E 0.6, rev $224.5M
Ultragenyx (RARE) versus Regis Corporation Common Stock (RGS) — a side-by-side from cached financials, not a winner call.
Ultragenyx (RARE) is a biotechnology company listed on US.
Regis Corporation Common Stock (RGS) is a personal services company listed on US.
Latest reported RARE revenue for 2026-06-30 was $350.0M. Net income was -$277.0M. RARE currently screens at market cap $2.79B.
Latest reported RGS revenue for 2026-06-30 was $224.5M. Net income was $6.9M. Revenue was up 6.8% from 2025-06-30 to 2026-06-30. RGS currently screens at market cap $56.5M and trailing P/E 0.6.
RARE currently screens at market cap $2.79B. RGS currently screens at market cap $56.5M and trailing P/E 0.6.
Not investment advice. Open the RARE and RGS stock pages for the full models.
Not investment advice.